<DOC>
	<DOCNO>NCT00003041</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness pyrazoloacridine treat woman refractory metastatic breast cancer .</brief_summary>
	<brief_title>Pyrazoloacridine Treating Women With Refractory Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy pyrazoloacridine patient refractory breast cancer . II . Determine toxic effect pyrazoloacridine patient . OUTLINE : Patients receive pyrazoloacridine IV 3 hour . Treatment repeat every 21 day 2-8 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 12-35 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>NSC 366140</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic breast cancer Bidimensionally measurable disease follow type require : Bidimensionally measurable lung lesion chest Xray , CT scan , MRI Palpable quantifiable lymph node least 2 x 2 cm Abdominal mass least 2 x 2 cm quantifiable CT scan Bidimensionally measurable liver metastasis least 2 x 2 cm Palpable hepatomegaly liver edge clearly define extend least 5 cm costal margin xiphoid process Unacceptable measurable disease : Diffuse lung infiltration unidimensionally measurable hilar lesion Pelvic mass indefinite dimension Bone metastases Pleural effusion ascites No brain metastasis Must fail progressed prior therapy relapse less 12 month therapy discontinuation Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 16 Sex : Female Menopausal status : Not specify Performance status : SWOG 02 Life expectancy : At least 6 month Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : SGOT great 2.5 time upper limit normal Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No history congestive heart failure , myocardial infarction within past 6 month , ventricular arrhythmia , ischemic heart disease require medication If necessary , ejection fraction least 50 % MUGA Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior malignancy past 5 year basal cell squamous cell carcinoma skin carcinoma situ cervix No serious illness active infection No seizure disorder require anticonvulsant therapy PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : See Disease Characteristics No 2 prior chemotherapy regimens metastatic disease One prior adjuvant chemotherapy regimen metastatic disease allow At least 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : One prior regimen hormonal therapy metastatic disease allow At least 3 week since prior hormonal therapy recover No concurrent hormonal corticosteroid therapy Radiotherapy : At least 4 week since prior radiotherapy le 25 % bone marrow No concurrent radiotherapy Surgery : At least 4 week since prior surgery recover No concurrent surgery Other : At least 4 week since prior treatment direct tumor recover No concurrent anticancer investigational therapy No concurrent participation another therapeutic clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>recurrent breast cancer</keyword>
</DOC>